{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:54:53Z","timestamp":1794333293889,"version":"4.9.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Janssen Pharmaceutical Companies of Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.euo.2025.07.009","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T10:17:46Z","timestamp":1758709066000},"page":"1558-1565","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Fibroblast Growth Factor Receptor Alteration Testing for >3600 Patients with Locally Advanced\/Metastatic Urothelial Cancer and Non\u2013muscle-invasive Bladder Cancer: An Analysis of the Global ANNAR Biomarker Study"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9203-4245","authenticated-orcid":false,"given":"Nobuaki","family":"Matsubara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohann","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severine","family":"Banek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a Perez","family":"Valderrama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris","family":"Deprince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyros","family":"Triantos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibu","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna Cody","family":"Carcione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanket","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene","family":"Siefker-Radtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.07.009_b0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2025.07.009_b0010","first-page":"15","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med Sci (Basel)"},{"key":"10.1016\/j.euo.2025.07.009_b0015","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211047352","article-title":"Metastatic urothelial cancer: a rapidly changing treatment landscape","volume":"13","author":"Stecca","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.euo.2025.07.009_b0020","doi-asserted-by":"crossref","first-page":"7892","DOI":"10.1245\/s10434-023-14051-9","article-title":"Cancer-specific survival of patients with non-muscle-invasive bladder cancer: a population-based analysis","volume":"30","author":"\u015alusarczyk","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.euo.2025.07.009_b0025","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-14-2329","article-title":"Targeting FGFR signaling in cancer","volume":"21","author":"Touat","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2025.07.009_b0030","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","article-title":"Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance","volume":"124","author":"Krook","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euo.2025.07.009_b0035","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2025.07.009_b0040","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.3390\/jcm11154483","article-title":"Prognostic value and clinical significance of FGFR genomic alterations (GAs) in metastatic urothelial cancer patients","volume":"11","author":"Sevillano Fern\u00e1ndez","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.euo.2025.07.009_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102530","article-title":"Role of FGFR3 in bladder cancer: treatment landscape and future challenges","volume":"115","author":"Ascione","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.euo.2025.07.009_b0050","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1158\/1535-7163.MCT-16-0589","article-title":"Discovery and pharmacological characterization of JNJ-42756493 (erdafitinib), a functionally selective small-molecule FGFR family inhibitor","volume":"16","author":"Perera","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.euo.2025.07.009_b0055","unstructured":"Janssen. BALVERSA\u00ae prescribing information; 2024. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/BALVERSA-pi.pdf."},{"key":"10.1016\/j.euo.2025.07.009_b0060","unstructured":"European Medicines Agency. Balversa summary of product characteristics; 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/balversa-epar-product-information_en.pdf."},{"key":"10.1016\/j.euo.2025.07.009_b0065","first-page":"125","article-title":"An overview of precision oncology basket and umbrella trials for clinicians","volume":"70","author":"Park","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2025.07.009_b0070","unstructured":"US Food & Drug Administration. Precision medicine; 2018. https:\/\/www.fda.gov\/medical-devices\/in-vitro-diagnostics\/precision-medicine."},{"key":"10.1016\/j.euo.2025.07.009_b0075","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1158\/1078-0432.CCR-21-3940","article-title":"Tumor genomic testing for >4,000 men with metastatic castration-resistant prostate cancer in the phase III trial PROfound (olaparib)","volume":"28","author":"Hussain","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2025.07.009_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2019.100493","article-title":"Biomarker-guided trials: challenges in practice","volume":"16","author":"Antoniou","year":"2019","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1016\/j.euo.2025.07.009_b0085","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.2147\/OTT.S97519","article-title":"Normalization of gene expression measurement of tissue samples obtained by transurethral resection of bladder tumors","volume":"9","author":"Pop","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.euo.2025.07.009_b0090","unstructured":"EAU guidelines. Presented at the EAU Annual Congress Madrid; 2025. ISBN 978-94-92671-29-5."},{"issue":"Suppl 9","key":"10.1016\/j.euo.2025.07.009_b0095","doi-asserted-by":"crossref","first-page":"S1489","DOI":"10.1016\/j.annonc.2022.10.180","article-title":"Treatment outcomes and FGFR alterations in unresectable locally advanced or metastatic urothelial cancer in Taiwan","volume":"33","author":"Li","year":"2022","journal-title":"Ann Oncol"},{"issue":"Suppl 4","key":"10.1016\/j.euo.2025.07.009_b0100","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1200\/JCO.2024.42.4_suppl.647","article-title":"Real world experience of FGFR gene alterations and clinical outcomes in advanced\/metastatic urothelial cancer in Japan: MONSTAR-SCREEN database study","volume":"42","author":"Matsubara","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.07.009_b0105","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2005.05.1771","article-title":"Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas","volume":"24","author":"Hern\u00e1ndez","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.07.009_b0110","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1158\/1078-0432.CCR-23-1283","article-title":"Clinical and genomic landscape of FGFR3-altered urothelial carcinoma and treatment outcomes with erdafitinib: a real-world experience","volume":"29","author":"Guercio","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2025.07.009_b0115","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.21037\/tau-20-1327","article-title":"Trends in urine biomarker discovery for urothelial bladder cancer: DNA, RNA, or protein?","volume":"10","author":"Humayun-Zakaria","year":"2021","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.euo.2025.07.009_b0120","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s00345-018-2543-9","article-title":"The current role and future directions of circulating tumor cells and circulating tumor DNA in urothelial carcinoma of the bladder","volume":"37","author":"Rink","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2025.07.009_b0125","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.3390\/cancers16122280","article-title":"Circulating tumor DNA in genitourinary cancers: detection, prognostics, and therapeutic implications","volume":"16","author":"Gerke","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.euo.2025.07.009_b0130","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2023.09.017","article-title":"Novel use of circulating tumor DNA to identify muscle-invasive and non-organ-confined upper tract urothelial carcinoma","volume":"85","author":"Huelster","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.07.009_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113368","article-title":"Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer","volume":"195","author":"Helal","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2025.07.009_b0140","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41467-020-20493-6","article-title":"Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer","volume":"12","author":"Vandekerkhove","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2025.07.009_b0145","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1038\/s41467-024-49153-9","article-title":"Development and deployment of a histopathology-based deep learning algorithm for patient prescreening in a clinical trial","volume":"15","author":"Juan Ramon","year":"2024","journal-title":"Nat Commun"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125002019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125002019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T08:42:14Z","timestamp":1778143334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125002019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2588931125002019"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.07.009","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fibroblast Growth Factor Receptor Alteration Testing for >3600 Patients with Locally Advanced\/Metastatic Urothelial Cancer and Non\u2013muscle-invasive Bladder Cancer: An Analysis of the Global ANNAR Biomarker Study","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}